Revenue
No reported data
AEON Biopharma, Inc. (AEON)
Price—Loading quote
Net income
2021
2022
2024
2025
Free cash flow
2022
2025
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2022 | 2021 | |
|---|---|---|---|---|
| Research & development | $4.1M | $14.2M | $34.8M | — |
| Operating expenses | $12.8M | — | $48.4M | $1.9M |
| Operating income | −$12.8M | $73.0M | −$48.4M | −$1.9M |
| EBITDAderived | −$12.7M | $73.1M | −$48.4M | — |
| Net income | −$39.2M | $42.0M | −$52.6M | $8.2M |
| Basic EPSper diluted share | -$3.95 | $77.74 | -$0.38 | — |
| Diluted EPSper diluted share | -$3.95 | $72.93 | -$0.38 | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 21, 2025Form 4 | FISCHER JOSTDirector | BuyClass A Common Stock | 60.0K | $0.49 | $29.4K | 266.8K |
| May 20, 2025Form 4 | FISCHER JOSTDirector | BuyClass A Common Stock | 60.0K | $0.51 | $30.6K | 206.8K |
| May 19, 2025Form 4 | FISCHER JOSTDirector | BuyClass A Common Stock | 50.0K | $0.50 | $25.0K | 146.8K |